Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Baldini, Luca
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant	Active, not recruiting	3	84	Europe	Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone	Fondazione EMN Italy Onlus	Multiple Myeloma, New Diagnosis Tumor	07/24	07/24
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial) Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2023 - Dec 2023: Data readout from DREAMM-8 trial in combination with pomalidomide and dexamethasone for 2L+ multiple myeloma Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submissions in EU for 2L+ multiple myeloma (based on DREAMM-7 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in US for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Dec 2023: Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Jul 2023 - Sep 2023 : Regulatory approval for 2L+ multiple myeloma (based on DREAMM-8 trial) Dec 2020 - Dec 2020 : Data from DREAMM-8 trial for multiple myeloma at ASH 2020 More	Recruiting	3	357	Europe, Japan, US, RoW	Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib	GlaxoSmithKline	Multiple Myeloma	01/24	05/29
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression	Active, not recruiting	2	82	Europe, US, RoW	brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone	Seagen Inc.	Peripheral T-cell Lymphoma	09/24	09/24
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication	Active, not recruiting	N/A	200	Europe		Fondazione Italiana Linfomi - ETS	Mantle Cell Lymphoma	10/23	06/24
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.	Recruiting	N/A	80	Europe		Fondazione Italiana Linfomi - ETS	Mantle Cell Lymphoma	12/23	12/23